"I'm pleased to announce we will make the new MenB and Men ACWY vaccines available in Wales."
“Wales is one of the first countries in the world to introduce a nationwide Men B vaccination programme to help tackle the effects of this disease, which can be devastating for children and their families."
“I'm sure the introduction of this vaccine as part of the routine childhood vaccination programme in Wales will offer families extra peace of mind."
“I am very pleased to be able to approve the introduction of the Men ACWY vaccine, which will protect teenagers against a number of forms of this disease, ensuring young people are protected at such an important time in their lives."
Mark Drakeford AM, Health Minister
The announcement brings Wales in line with other countries across the UK.
Men B programme from September
An infant Meningococcal Group B (Men B) immunisation programme will begin in September. This vaccine will be offered for babies starting at two months of age, followed by another dose at four months and a booster dose at 12 months.
There will also be a limited catch-up programme for infants who are due their three and four month vaccinations in September.
A Meningitis ACWY vaccine programme will begin in August with 17 to 18-year-olds (School year 13) and older university entrants (aged 19 to 25) being offered the vaccine.
We’re delighted to see that these programmes are being introduced to protect the country's newborn babies and young people from the devastation meningitis causes – these measures will start to save lives straight away and for years to come.
Don’t become complacent
Whilst this is good news it does not mean that meningitis is beaten. Our message remains ‘Don’t become complacent about meningitis’ – there are still strains without vaccines and there will still be people who are not protected by these vaccine programmes.
It’s vital to learn the signs and symptoms, stay vigilant and seek immediate medical help if you suspect the disease.
We will continue campaigning to extend the availability of these vaccines to other at-risk groups.
For more information see our Q and A